Abu Dhabi Health" It announces a partnership with “Jimpio” to develop genetic treatments for rare diseases

Abu Dhabi, July 5 / WAM / The Department of Health in Abu Dhabi, and the company “M42”, the global specialized in the field of health and artificial intelligence, technology and genome sciences, and the Burjahth Group, the largest hospital and health guarantee group in the Middle East, announced a partnership with “Jimpio Thurabiotics”, the innovative global biotechnology company committed to developing genetic treatments for diseases Rare.

The Department of Health in Abu Dhabi said that the announcement of the partnership came on the sidelines of the activities of the International Conference of the Innovation Organization in Biotechnology 2025, which was held in Boston, in the United States of America, and the senior leaders of Jimpio and leadership figures in the health and life science system in Abu Dhabi.

The parties involved jointly discussed cooperation opportunities to establish specialized manufacturing and research centers within the academic health institutions in Abu Dhabi, enabling patients in the Middle East and North Africa region to reach the previous clinical trials and genetic treatments ultimately.

This ambitious cooperation will be launched through a clinical trial aimed at developing genetic treatments for children with SMA1 spinal muscle atrophy, in a universal precedent to expand access to treatments that save patients’ lives.

Dr. Mohamed Al -Amiri, Acting Director of Genome and Biological Bank at the Department of Health in Abu Dhabi, said that our partnership with Jimpio is a vital step that establishes Abu Dhabi’s world leader in developing genetic treatments for rare diseases by taking advantage of the capabilities of the Emirati genome program.

“We in the Health Department are committed to drawing new features of innovation, early diagnosis and personal care by enhancing the emirate’s capabilities to develop, test and expand innovative treatments, as we proceed with these efforts towards developing realistic applications of life sciences while reviving the hopes of patients and families who were exhausted by rare diseases in the region and abroad.”

He explained that this cooperation will unite the common vision and technology available to enhance the research and development system in genetic therapy in Abu Dhabi, which will constitute a regional center for the “Jimpio” applied and clinical research activities, and a leading institution in its class will be established to develop genetic therapy and research in the emirate, as a joint project between “M42” and “Jimpio” and in addition, regional access to genetic medicines will be coordinated For “Jimpio” through research and genetic treatment centers in Abu Dhabi.

He said, “With the support of the advanced infrastructure in the Emirate of Abu Dhabi, the ambitious policies, and the” Health, Medicine and Fitness Complex for a sustainable life, “Abu Dhabi provides simplified procedures for licenses and joint marketing, as well as joint investment programs and tax exemption for emerging biotechnology companies and establishes these ways of support.

For his part, Dr. Jim Wilson, the founder, president and executive director of Jimpio said that this important partnership will provide a pivotal role in providing life -saving treatments for rare global diseases .. And the concerned authorities in Abu Dhabi are working to build a global system for genetic treatment that will have a great impact on the future of life sciences, where we look together to employ scientific innovation to achieve ambitious goals Upon accelerating development efforts in the most urgent areas. “

Dimitris Mogafasilis, CEO of the M42 Group, said that this partnership will contribute to the supply of Abu Dhabi’s efforts to open new horizons in the future of health, thanks to our integrated system based on artificial intelligence and data, and the progress made by the emirate in the fields of careful medicine, prevention and prediction, this cooperation will expand the scope of the impact of the Emirati genome program to include genetic treatments that target diseases Rare, while M42 is focused on developing genomic visions, combating rare diseases, and saving the lives of many, as our partnership with the Department of Health in Abu Dhabi and Jimpio will accelerate this effort, ensuring that members of society in the UAE and outside the genetic treatments they need for a longer and healthier life. “

He added that this strategic partnership will strengthen the great steps that Abu Dhabi recently made in the field of genetic treatments for rare diseases and careful medicine. The emirate has expanded its capabilities in the genome science through the Emirati genome program, which succeeded in setting the sequence of more than 800 samples, which established one of the most developed genetic databases in the world.

“Abu Dhabi continues to consolidate its leadership in providing the latest genetic treatments, it is expanded to reach treatments that can save the lives of patients and was not previously available in the region.

Through continuous investment in scientific research, human cadres, and infrastructure, the emirate entrenches its regionally leading place in life sciences and medical innovations.

His Excellency Rashid Saif Al -Qubaisi, CEO of Operations at the Burelth Group, said that this cooperation will embody the growing role of Abu Dhabi as a global center for innovation in health care, through cooperation with Jimpio and the rest of the strategic partners, we look forward to expanding the scope of access to advanced genetic treatments, and enhancing the commitment of the Emirate of Abu Dhabi to the effective contribution to responding to the most complicated health challenge in the world and pride In Burhailth, our participation through our integrated research capabilities and our commitment to clinical excellence, in line with the vision of the Department of Health in Abu Dhabi to achieve treatment results that enhance the lives of patients in the region and abroad.

It is noteworthy that a delegation headed by the Department of Health in Abu Dhabi made a strategic visit to the United States of America during the period from 15 to 21 June 2025, where the visit focused on exchanging visions and signing strategic partnerships aimed at employing advanced systems in both countries to accelerate the frequency of innovation and achieve concrete results.

The delegation represented the innovation system in Abu Dhabi, and the inclusion of a group of parties from various sectors, including the Abu Dhabi Investment Office, Mabbala Bayu, M42, Masdar City, Caesad, Burjahth, Al -Ittihad Shipping, New York University Abu Dhabi, Khalifa University, Mohammed bin Zayed University of Artificial Intelligence and Start Ad.

• For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and Twitter